Search

Your search keyword '"Gerber, David E."' showing total 432 results
Start Over Author "Gerber, David E." Search Limiters Full Text
432 results on '"Gerber, David E."'

2. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

Author

Shaverdashvili, Khvaramze, Reyes, Vincent, Wang, Hong, Mehta, Dhaval, Marsh, Christopher, Waas, John K., VanderWeele, Robert A., Peracha, Sajid M., Liang, Hongmei, Socinski, Mark A., Gerber, David E., Dowell, Jonathan E., and Villaruz, Liza C.

Published
2023
Full Text
View/download PDF

6. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Author

Gong, Ke, Guo, Gao, Gerber, David E, Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D, Hatanpaa, Kimmo J, Kernstine, Kemp, Cai, Ling, Xie, Yang, Zhu, Hong, Fattah, Farjana J, Zhang, Shanrong, Takahashi, Masaya, Mukherjee, Bipasha, Burma, Sandeep, Dowell, Jonathan, Dao, Kathryn, Papadimitrakopoulou, Vassiliki A, Olivas, Victor, Bivona, Trever G, Zhao, Dawen, and Habib, Amyn A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung, Lung Cancer, Genetics, A549 Cells, Animals, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, ErbB Receptors, Female, Humans, Lung Neoplasms, Mice, Mice, Nude, MicroRNAs, Neoplasm Proteins, Neoplasms, Experimental, RNA, Messenger, RNA, Neoplasm, Tumor Necrosis Factor-alpha, Lung cancer, Protein kinases, Therapeutics, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Although aberrant EGFR signaling is widespread in cancer, EGFR inhibition is effective only in a subset of non-small cell lung cancer (NSCLC) with EGFR activating mutations. A majority of NSCLCs express EGFR wild type (EGFRwt) and do not respond to EGFR inhibition. TNF is a major mediator of inflammation-induced cancer. We find that a rapid increase in TNF level is a universal adaptive response to EGFR inhibition in NSCLC, regardless of EGFR status. EGFR signaling actively suppresses TNF mRNA levels by inducing expression of miR-21, resulting in decreased TNF mRNA stability. Conversely, EGFR inhibition results in loss of miR-21 and increased TNF mRNA stability. In addition, TNF-induced NF-κB activation leads to increased TNF transcription in a feed-forward loop. Inhibition of TNF signaling renders EGFRwt-expressing NSCLC cell lines and an EGFRwt patient-derived xenograft (PDX) model highly sensitive to EGFR inhibition. In EGFR-mutant oncogene-addicted cells, blocking TNF enhances the effectiveness of EGFR inhibition. EGFR plus TNF inhibition is also effective in NSCLC with acquired resistance to EGFR inhibition. We suggest concomitant EGFR and TNF inhibition as a potentially new treatment approach that could be beneficial for a majority of lung cancer patients.

Published
2018

7. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

Author

von Itzstein, Mitchell S., primary, Yang, Yuqiu, additional, Wang, Yiqing, additional, Hsiehchen, David, additional, Sheffield, Thomas Y., additional, Fattah, Farjana, additional, Popat, Vinita, additional, Ahmed, Murtaza, additional, Homsi, Jade, additional, Dowell, Jonathan E., additional, Rashdan, Sawsan, additional, Lohrey, Jay, additional, Hammers, Hans J., additional, Hughes, Randall S., additional, Wang, Tao, additional, Xie, Yang, additional, and Gerber, David E., additional

Published
2024
Full Text
View/download PDF

9. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non–Small-Cell Lung Cancer (RTOG 3505)

Author

Gerber, David E, Urbanic, James J, Langer, Corey, Hu, Chen, Chang, I-Fen, Lu, Bo, Movsas, Benjamin, Jeraj, Robert, Curran, Walter J, and Bradley, Jeffrey D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Lung, Lung Cancer, Clinical Research, Clinical Trials and Supportive Activities, Cancer, 6.5 Radiotherapy and other non-invasive therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Cisplatin, Combined Modality Therapy, Etoposide, Humans, Immunotherapy, Lung Neoplasms, Middle Aged, Neoplasm Staging, Nivolumab, Placebo Effect, Proportional Hazards Models, Research Design, Survival Analysis, Young Adult, Abscopal effect, Checkpoint inhibitor, Coprimary end points, Programmed death 1, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Radiation Therapy Oncology Group (RTOG) 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small-cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiotherapy to 60 Gy with concurrent cisplatin 50 mg/m2 intravenously (I.V.) on days 1, 8, 29, and 36, and etoposide 50 mg/m2 I.V. on days 1 to 5 and days 29 to 33. Between 4 and 12 weeks after completion of concurrent chemoradiation, eligible patients will be randomized to the anti-programmed death 1 (PD-1) monoclonal antibody nivolumab 240 mg I.V. or placebo every 2 weeks for up to 1 year. The primary end points are overall survival (OS) and progression-free survival (PFS), as determined by central independent radiology review. Secondary objectives include toxicity assessment, patient-reported outcomes and quality of life, and OS and PFS in programmed death ligand 1 (PD-L1) expressors (≥ 1%) and PD-L1 nonexpressors (< 1%). Assuming a rate of 16.7% due to ineligibility and dropout before randomization, a total of 660 patients will be enrolled to ensure 550 patients will be randomized after completion of chemoradiation. This sample size will provide ≥ 90% power to detect a hazard ratio of 0.7 for OS with 2-sided type I error of 0.04, and to detect a hazard ratio of 0.667 for PFS 2-sided type I error of 0.01. (NCT02768558).

Published
2017

10. TTFields (Tumor Treating Fields) associés au traitement standard dans les cancers du poumon non à petites cellules métastatiques en progression après sels de platine :Étude internationale, randomisée de phase 3 LUNAR

Author

Berghmans, Thierry, Leal, Teresinha, KOTECHA, RUPESH, Ramlau, Rodryg, Zhang, L, Milanowski, Janusz, Cobo, Manuel, Roubec, Jaromir, Petruzelka, L, Havel, Libor, Kalmadi, Jujith, Ward, James, Andric, Zoran, Gerber, David, E, Kloecker, Goetz, Panikkar, Rajiv, Aerts, J., Delmonte, Angelo, Pless, Miklos, Langer, C., Berghmans, Thierry, Leal, Teresinha, KOTECHA, RUPESH, Ramlau, Rodryg, Zhang, L, Milanowski, Janusz, Cobo, Manuel, Roubec, Jaromir, Petruzelka, L, Havel, Libor, Kalmadi, Jujith, Ward, James, Andric, Zoran, Gerber, David, E, Kloecker, Goetz, Panikkar, Rajiv, Aerts, J., Delmonte, Angelo, Pless, Miklos, and Langer, C.

Abstract

info:eu-repo/semantics/published

Published
2024

12. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.

Author

Mack, Philip C., Hsu, Chih-Yuan, Rodilla, Ananda M., Gomez, Jorge E., Cagan, Jazz, Huang, Yuanhui, Tavolacci, Sooyun, Valanparambil, Rajesh M., Rohs, Nicholas, Brody, Rachel, Nichols, Brittney, Carreño, Juan Manuel, Bhalla, Sheena, Rolfo, Christian, Gerber, David E., Moore, Amy, King, Jennifer C., Ahmed, Rafi, Minna, John D., and Bunn Jr., Paul A.

Subjects
SARS-CoV-2, COVID-19 vaccines, BOOSTER vaccines, GENERALIZED estimating equations, INFLUENZA vaccines
Abstract

In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging, due to evolving treatments, infections, vaccinations, and health status. The objective was to develop a time-dependent regression model elucidating individual contributions of factors influencing SAb levels in LC patients using a prospective, longitudinal, multi-institutional cohort study initiated in January 2021. The study evaluated 296 LC patients—median age 69; 55% female; 50% stage IV. Blood samples were collected every three months to measure SAb levels using FDA-approved ELISA. Asymptomatic and unreported infections were documented through measurement of anti-nucleocapsid Ab levels (Meso Scale Discovery). Associations between clinical characteristics and titers were evaluated using a time-dependent linear regression model with a generalized estimating equation (GEE), considering time-independent variables (age, sex, ethnicity, smoking history, histology, and stage) and time-dependent variables (booster vaccinations, SARS-CoV-2 infections, cancer treatment, steroid use, and influenza vaccination). Significant time-dependent effects increasing titer levels were observed for prior SARS-CoV-2 infection (p < 0.001) and vaccination/boosters (p < 0.001). Steroid use (p = 0.043) and chemotherapy (p = 0.033) reduced titer levels. Influenza vaccination was associated with increased SAb levels (p < 0.001), independent of SARS-CoV-2 vaccine boosters. Prior smoking significantly decreased titers in females (p = 0.001). Age showed no association with titers. This GEE-based linear regression model unveiled the nuanced impact of multiple variables on patient anti-spike Ab levels over time. After controlling for the major influences of vaccine and SARS-CoV-2 infections, chemotherapy and steroid use were found to have negatively affected titers. Smoking in females significantly decreased titers. Surprisingly, influenza vaccinations were also significantly associated, likely indirectly, with improved SARS-CoV-2 titers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Author

Rodilla, Ananda M., primary, Valanparambil, Rajesh M., additional, Mack, Philip C., additional, Hsu, Chih-Yuan, additional, Cagan, Jazz, additional, Tavolacci, Sooyun C., additional, Carreño, Juan Manuel, additional, Brody, Rachel, additional, Moore, Amy, additional, King, Jennifer C., additional, Gomez, Jorge E., additional, Rohs, Nicholas, additional, Rolfo, Christian, additional, Bunn, Paul A., additional, Gerber, David E., additional, Minna, John D., additional, Krammer, Florian, additional, Ramalingam, Suresh S., additional, García-Sastre, Adolfo, additional, Shyr, Yu, additional, Ahmed, Rafi, additional, and Hirsch, Fred R., additional

Published
2023
Full Text
View/download PDF

15. Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.

Author

Gerber, David E, Wang, Yating, Ramalingam, Suresh S, Bhalla, Sheena, Sun, Zhuoxin, Borghaei, Hossein, Brahmer, Julie R, and Schiller, Joan H

Subjects
THERAPEUTIC use of antineoplastic agents, PEARSON correlation (Statistics), RISK assessment, BEVACIZUMAB, TREATMENT effectiveness, CARBOPLATIN, MANN Whitney U Test, CHI-squared test, MULTIVARIATE analysis, LOG-rank test, CANCER chemotherapy, CANCER cells, LUNG cancer, TUMOR classification, PACLITAXEL, CONFIDENCE intervals, SURVIVAL analysis (Biometry), OVERALL survival, PROPORTIONAL hazards models
Abstract

Background Mixed response (MR), a scenario featuring discordant tumor changes, has been reported primarily with targeted therapies or immunotherapy. We determined the incidence and prognostic significance of MR in advanced non–small cell lung cancer (NSCLC) treated with cytotoxic chemotherapy. Patients and Methods We analyzed patient-level data from ECOG-ACRIN E5508 (carboplatin-paclitaxel + bevacizumab induction followed by randomization to maintenance therapy regimens). For patients with at least 2 target lesions and available measurements after cycle 2, we characterized response as homogeneous response (HR, similar behavior of all lesions), MR (similar behavior but >30% difference in magnitude of best and least responding lesions), or true mixed response (TMR, best and least responding lesions showing different behavior: ≥10% growth versus ≥10% shrinkage). We compared category characteristics using Mann-Whitney U and Chi-square tests, and overall survival (OS) using log-rank test and Cox models. Results Among 965 evaluable patients, HR occurred in 609 patients (63%), MR in 208 (22%), and TMR in 148 (15%). Median OS was 13.6 months for HR, 12.0 months for MR, and 7.6 months for TMR (P  < .001). Compared to HR, TMR had inferior OS among stable disease cases (HR 1.62; 95% CI, 1.23-2.12; P  < .001) and a trend toward inferior OS among progressive disease cases (HR 1.39; 95% CI, 0.83-2.33; P  = .2). In multivariate analysis, TMR was associated with worse OS (HR 1.48; 95% CI, 1.22-1.79; P  < .001). Conclusion True mixed response occurs in a substantial minority of lung cancer cases treated with chemotherapy and independently confers poor prognosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. T-cell tolerant fraction as a predictor of immune-related adverse events

Author

Ostmeyer, Jared, primary, Park, Jason Y, additional, von Itzstein, Mitchell S, additional, Hsiehchen, David, additional, Fattah, Farjana, additional, Gwin, Mary, additional, Catalan, Rodrigo, additional, Khan, Shaheen, additional, Raj, Prithvi, additional, Wakeland, Edward K, additional, Xie, Yang, additional, and Gerber, David E, additional

Published
2023
Full Text
View/download PDF

18. Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors

Author

Mundra, Vatsala, primary, Yang, Yuqiu, additional, von Itzstein, Mitchell S., additional, Fattah, Farjana, additional, Gonugunta, Amrit S., additional, Hannan, Raquibul, additional, Pop, Laurentiu M., additional, Zhang, Yuanyuan, additional, Wang, Yiqing, additional, Sheffield, Thomas, additional, Xie, Yang, additional, Dowell, Jonathan E., additional, Homsi, Jade, additional, Rashdan, Sawsan, additional, Park, Jason, additional, Li, Quan-Zhen, additional, Wakeland, Edward K., additional, and Gerber, David E., additional

Published
2023
Full Text
View/download PDF

22. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

Author

Gerber, David E., Beg, M. Shaalan, Fattah, Farjana, Frankel, Arthur E., Fatunde, Oluwatomilade, Arriaga, Yull, Dowell, Jonathan E., Bisen, Ajit, Leff, Richard D., Meek, Claudia C., Putnam, William C., Kallem, Raja Reddy, Subramaniyan, Indhumathy, Dong, Ying, Bolluyt, Joyce, Sarode, Venetia, Luo, Xin, Xie, Yang, Schwartz, Brian, and Boothman, David A.

Published
2018
Full Text
View/download PDF

23. PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients

Author

Tavolacci, Sooyun, primary, Mack, Philip C., additional, Gomez, Jorge E., additional, Rohs, Nicholas, additional, Rodilla, Ananda M., additional, De Miguel Perez, Diego, additional, Carreño, Juan Manuel, additional, Hsu, Chin-Yuan, additional, Cagan, Jazz, additional, Rolfo, Christian, additional, Moore, Amy, additional, Brody, Rachel I., additional, King, Jennifer C., additional, Gerber, David E., additional, Henschke, Claudia I., additional, Yankelevitz, David F., additional, Minna, John D., additional, Bunn, Paul, additional, García-Sastre, Adolfo, additional, Krammer, Florian, additional, Shyr, Yu, additional, and Hirsch, Fred R., additional

Published
2023
Full Text
View/download PDF

24. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

Author

Leal, Ticiana, KOTECHA, RUPESH, Ramlau, Rodryg, Milanowski, Janusz, Cobo, Manuel, Roubec, Jaromir, Petruzelka, L, Havel, Libor, Kalmadi, Jujith, Ward, Jeffrey, Andric, Zoran, Berghmans, Thierry, Gerber, David, E, Kloecker, Goetz, Panikkar, Rajiv, Aerts, Joachim J.G.J.V., Delmonte, Angelo, Pless, Miklos, Greil, Richard, Rolfo, Christian, A Beccara, Wallace, Eaton, Michael, Iqbal, Mussawar, Langer, Corey, Leal, Ticiana, KOTECHA, RUPESH, Ramlau, Rodryg, Milanowski, Janusz, Cobo, Manuel, Roubec, Jaromir, Petruzelka, L, Havel, Libor, Kalmadi, Jujith, Ward, Jeffrey, Andric, Zoran, Berghmans, Thierry, Gerber, David, E, Kloecker, Goetz, Panikkar, Rajiv, Aerts, Joachim J.G.J.V., Delmonte, Angelo, Pless, Miklos, Greil, Richard, Rolfo, Christian, A Beccara, Wallace, Eaton, Michael, Iqbal, Mussawar, and Langer, Corey

Abstract

Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell survival, info:eu-repo/semantics/inPress

Published
2023

25. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Author

Rudin, Charles M, primary, Pandha, Hardev S, additional, Zibelman, Matthew, additional, Akerley, Wallace L, additional, Harrington, Kevin J, additional, Day, Daphne, additional, Hill, Andrew G, additional, O'Day, Steven J, additional, Clay, Timothy D, additional, Wright, Gavin M, additional, Jennens, Ross R, additional, Gerber, David E, additional, Rosenberg, Jonathan E, additional, Ralph, Christy, additional, Campbell, David C, additional, Curti, Brendan D, additional, Merchan, Jaime R, additional, Ren, Yixin, additional, Schmidt, Emmett V, additional, Guttman, Lisa, additional, and Gupta, Sumati, additional

Published
2023
Full Text
View/download PDF

26. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Author

Morgensztern, Daniel, Campo, Meghan J., Dahlberg, Suzanne E., Doebele, Robert C., Garon, Edward, Gerber, David E., Goldberg, Sarah B., Hammerman, Peter S., Heist, Rebecca S., Hensing, Thomas, Horn, Leora, Ramalingam, Suresh S., Rudin, Charles M., Salgia, Ravi, Sequist, Lecia V., Shaw, Alice T., Simon, George R., Somaiah, Neeta, Spigel, David R., Wrangle, John, Johnson, David, Herbst, Roy S., Bunn, Paul, and Govindan, Ramaswamy

Published
2015
Full Text
View/download PDF

30. Survival of cancer survivors with a new pancreatic cancer diagnosis

Author

Pruitt, Sandi L., primary, Tavakkoli, Anna, additional, Zhu, Hong, additional, Heitjan, Daniel F., additional, Gerber, David E., additional, Singal, Amit G., additional, Halm, Ethan A., additional, Beg, Muhammad Shaalan, additional, Maddineni, Bhumika, additional, Kansagra, Ankit J., additional, and Murphy, Caitlin C., additional

Published
2022
Full Text
View/download PDF

31. Oncologic emergencies and urgencies: A comprehensive review

Author

Gould Rothberg, Bonnie E., primary, Quest, Tammie E., additional, Yeung, Sai‐Ching J., additional, Pelosof, Lorraine C., additional, Gerber, David E., additional, Seltzer, Justin A., additional, Bischof, Jason J., additional, Thomas, Charles R., additional, Akhter, Nausheen, additional, Mamtani, Mira, additional, Stutman, Robin E., additional, Baugh, Christopher W., additional, Anantharaman, Venkataraman, additional, Pettit, Nicholas R., additional, Klotz, Adam D., additional, Gibbs, Michael A., additional, and Kyriacou, Demetrios N., additional

Published
2022
Full Text
View/download PDF

32. Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Author

Mack, Philip C., primary, Gomez, Jorge E., additional, Rodilla, Ananda M., additional, Carreño, Juan Manuel, additional, Hsu, Chih-Yuan, additional, Rolfo, Christian, additional, Meshulami, Noy, additional, Moore, Amy, additional, Brody, Rachel I., additional, King, Jennifer C., additional, Treatman, Jacquelyn, additional, Lee, Sooyun, additional, Raskin, Ariel, additional, Srivastava, Komal, additional, Gleason, Charles R., additional, de Miguel-Perez, Diego, additional, Tcheou, Johnstone, additional, Bielak, Dominika, additional, Acharya, Rashmi, additional, Gerber, David E., additional, Rohs, Nicholas, additional, Henschke, Claudia I., additional, Yankelevitz, David F., additional, Simon, Viviana, additional, Minna, John D., additional, Bunn, Paul A., additional, García-Sastre, Adolfo, additional, Krammer, Florian, additional, Shyr, Yu, additional, Hirsch, Fred R., additional, Andre, D., additional, Alshammary, H., additional, van Bakel, H., additional, Bermúdez-González, M.C., additional, Cai, G., additional, Cognigni, C., additional, Floda, D., additional, Firpo, A., additional, Kleiner, G., additional, Lyttle, N., additional, Mendez, W., additional, Mulder, L.C.F., additional, Oostenink, A., additional, Rooker, A., additional, Salimbangon, A., additional, Saksena, M., additional, Sominsky, L., additional, and Sordillo, E.M., additional

Published
2022
Full Text
View/download PDF

34. Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

Author

von Itzstein, Mitchell S., primary, Gonugunta, Amrit S., additional, Sheffield, Thomas, additional, Homsi, Jade, additional, Dowell, Jonathan E., additional, Koh, Andrew Y., additional, Raj, Prithvi, additional, Fattah, Farjana, additional, Wang, Yiqing, additional, Basava, Vijay S., additional, Khan, Shaheen, additional, Park, Jason Y., additional, Popat, Vinita, additional, Saltarski, Jessica M., additional, Gloria-McCutchen, Yvonne, additional, Hsiehchen, David, additional, Ostmeyer, Jared, additional, Xie, Yang, additional, Li, Quan-Zhen, additional, Wakeland, Edward K., additional, and Gerber, David E., additional

Published
2022
Full Text
View/download PDF

38. Association between immune-related adverse event timing and treatment outcomes

Author

Hsiehchen, David, primary, Naqash, Abdul Rafeh, additional, Espinoza, Magdalena, additional, Von Itzstein, Mitchell S., additional, Cortellini, Alessio, additional, Ricciuti, Biagio, additional, Owen, Dwight H., additional, Laharwal, Mehak, additional, Toi, Yukihiro, additional, Burke, Michael, additional, Xie, Yang, additional, and Gerber, David E., additional

Published
2022
Full Text
View/download PDF

39. Humoral and cellular correlates of a novel immune-related adverse event and its treatment

Author

Gonugunta, Amrit S, primary, von Itzstein, Mitchell S, additional, Mu-Mosley, Hong, additional, Fattah, Farjana, additional, Farrar, J David, additional, Mobely, Angela, additional, Rashdan, Sawsan, additional, Lai, Sunny, additional, Bhai, Salman F, additional, Bermas, Bonnie L, additional, Karp, David, additional, Li, Quan-Zhen, additional, Wakeland, Edward K, additional, and Gerber, David E, additional

Published
2021
Full Text
View/download PDF

40. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Author

Bunn, Paul A., Jr., Minna, John D., Augustyn, Alexander, Gazdar, Adi F., Ouadah, Youcef, Krasnow, Mark A., Berns, Anton, Brambilla, Elisabeth, Rekhtman, Natasha, Massion, Pierre P., Niederst, Matthew, Peifer, Martin, Yokota, Jun, Govindan, Ramaswamy, Poirier, John T., Byers, Lauren A., Wynes, Murry W., McFadden, David G., MacPherson, David, Hann, Christine L., Farago, Anna F., Dive, Caroline, Teicher, Beverly A., Peacock, Craig D., Johnson, Jane E., Cobb, Melanie H., Wendel, Hans-Guido, Spigel, David, Sage, Julien, Yang, Ping, Pietanza, Catherine M., Krug, Lee M., Heymach, John, Ujhazy, Peter, Zhou, Caicun, Goto, Koichi, Dowlati, Afshin, Christensen, Camilla Laulund, Park, Keunchil, Einhorn, Lawrence H., Edelman, Martin J., Giaccone, Giuseppe, Gerber, David E., Salgia, Ravi, Owonikoko, Taofeek, Malik, Shakun, Karachaliou, Niki, Gandara, David R., Slotman, Ben J., Blackhall, Fiona, Goss, Glenwood, Thomas, Roman, Rudin, Charles M., and Hirsch, Fred R.

Published
2016
Full Text
View/download PDF

41. Survival of cancer survivors with a new pancreatic cancer diagnosis.

Author

Pruitt, Sandi L., Tavakkoli, Anna, Zhu, Hong, Heitjan, Daniel F., Gerber, David E., Singal, Amit G., Halm, Ethan A., Beg, Muhammad Shaalan, Maddineni, Bhumika, Kansagra, Ankit J., and Murphy, Caitlin C.

Subjects
CANCER diagnosis, CANCER survivors, PANCREATIC cancer, PROPORTIONAL hazards models, CARCINOMA in situ, PANCREATIC intraepithelial neoplasia, PROSTATE cancer
Abstract

Background: Persons newly diagnosed with pancreas cancer and who have survived a previous cancer are often excluded from clinical trials, despite limited evidence about their prognosis. We examined the association between previous cancer and overall survival. Methods: This US population‐based cohort study included older adults (aged ≥66 years) diagnosed with pancreas cancer between 2005 and 2015 in the linked Surveillance, Epidemiology, and End Results‐Medicare data. We used Cox proportional hazards models to estimate stage‐specific effects of previous cancer on overall survival, adjusting for sociodemographic, treatment, and tumor characteristics. Results: Of 32,783 patients, 18.7% were previously diagnosed with another cancer. The most common previous cancers included prostate (29.0%), breast (18.9%), or colorectal (9.7%) cancer. More than half of previous cancers (53.9%) were diagnosed 5 or more years prior to pancreas cancer diagnosis or at an in situ or localized stage (47.8%). The proportions of patients surviving 1, 3, and 5 years after pancreas cancer were nearly identical for those with and without previous cancer. Median survival in months was as follows for those with and without previous cancer respectively: 7 versus 8 (Stage 0/I), 10 versus 10 (Stage II), 7 versus 7 (Stage III), and 3 versus 2 (Stage IV). Cox models indicated that patients with previous cancer had very similar or statistically equivalent survival to those with no previous cancer. Conclusions: Given nearly equivalent survival compared to those without previous cancer, cancer survivors newly diagnosed with pancreas cancer should be considered for inclusion in pancreas cancer clinical trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results